Price
$15.25
Increased by 0.00%
Dollar Volume
7.90 M
ADR%
0.14
Earnings Report Date (estimate)
Feb 22, 23 (N/A)
Market Cap.
753.62 M
Shares Float
43.85 M
Shares Outstanding
49.39 M
Beta
-0.06
Price / Earnings
-10.36
BPR
471.86
20D Range
15.17 15.25
50D Range
15.04 15.26
200D Range
4.81 15.37
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 3, 22 -0.27
Decreased by -124.77%
-0.44
Increased by +38.64%
Aug 4, 22 -0.32
Increased by +55.56%
-0.56
Increased by +42.86%
May 5, 22 -0.66
Increased by +1.49%
-0.65
Decreased by -1.54%
Feb 24, 22 1.09
Increased by +251.39%
-0.67
Increased by +262.69%
Feb 23, 22 1.09
Increased by +237.97%
-0.67
Increased by +262.69%
Nov 4, 21 -0.72
Decreased by -10.77%
-0.62
Decreased by -16.13%
Aug 4, 21 -0.67
Increased by +19.28%
-0.64
Decreased by -4.69%
May 5, 21 -0.72
Increased by +13.25%
-0.68
Decreased by -5.88%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 36.13 M
Increased by +23.25%
-26.83 M
Increased by +32.41%
Decreased by -74.25%
Increased by +45.16%
Jun 30, 22 33.31 M
Increased by +22.53%
-19.37 M
Increased by +49.93%
Decreased by -58.15%
Increased by +59.14%
Mar 31, 22 29.84 M
Increased by +29.89%
-35.89 M
Increased by +14.47%
Decreased by -120.30%
Increased by +34.15%
Dec 31, 21 114.67 M
Increased by +364.55%
45.53 M
Increased by +198.69%
Increased by +39.71%
Increased by +121.24%
Sep 30, 21 29.31 M
Increased by +45.97%
-39.69 M
Decreased by -0.11%
Decreased by -135.40%
Increased by +31.42%
Jun 30, 21 27.18 M
Increased by +50.75%
-38.69 M
Increased by +19.71%
Decreased by -142.31%
Increased by +46.74%
Mar 31, 21 22.97 M
Increased by +12.92%
-41.96 M
Increased by +14.58%
Decreased by -182.69%
Increased by +24.36%
Dec 31, 20 24.68 M
Increased by +0.11%
-46.14 M
Increased by +16.21%
Decreased by -186.92%
Increased by +16.30%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.